![]() ![]() Emerging Treatment Could be a Weight Loss Surgery Alternative. May 9, 2. 01. 7 - - A nonsurgical weight loss treatment for obesity could offer an alternative to surgery. ![]() ![]() Achieve healthy weight loss without surgery with the ORBERA Gastric Balloon. Explore weight loss programs designed to support a new healthy lifestyle. The Non-Surgical Weight Loss Procedure That Takes 40 Minutes. Endoscopic sleeve gastroplasty is a new option for people who are looking to lose weight, but may not. The procedure, called endoscopic sleeve gastroplasty, or ESG, cinches a patient’s stomach to make it smaller. Doctors use an endoscope - - a tube with a light and camera attached to it - - to perform the treatment. In a study presented at the Digestive Disease Week conference, researchers looked at how the emerging treatment compared with two types of weight loss surgery. The sleeve procedure . Sharaiha, MD, assistant professor of medicine at Weill Cornell Medicine, who led the study. She says the procedure makes the stomach shorter and narrower. As a result, patients eat much less food. And because the stomach's smaller, the food stays in it longer, and it takes longer to go down. Sharaiha performs the endoscopic sleeve (accordion procedure) in New York. The “endoscopic sleeve” procedure is similar to the gastric sleeve surgery, but is. New Endoscopic Sleeve Gastroplasty Procedure announced by Mayo Clinic. Discover the differences to Gastric Sleeve Surgery, VSG. As with surgery, endoscopic sleeve gastroplasty is only for someone who is obese - - with a body mass index (BMI) over 3. Although bariatric surgery has helped many people lose weight, a 2. Experts say the new treatment could give some people an alternative. How the New Procedure Stacks Up. Sharaiha is a consultant for Apollo, which makes the suturing device used in the treatment. She followed 2. 78 obese men and women for a year after they had one of three procedures. Of those: 9. 1 had endoscopic sleeve gastroplasty. It requires a surgeon to make several small cuts. The patients who tried the endoscopic sleeve gastroplasty had the lowest BMI of the three groups. Endoscopic Sleeve Gastroplasty (ESG) is the term given to a new weight loss procedure pioneered at the Mayo Clinic in 2012, and now in use in a number of centres. A new type of weight-loss procedure offers an alternative to traditional bariatric surgery for people who are mildly to moderately obese. ![]() Theirs was 3. 9, compared with an average BMI of 4. On average, the patients were in their 4. At one year, the weight loss was: 2. Continued. Although the treatment didn’t bring the most weight loss, Sharaiha says it has a much lower complication rate and cost than standard bariatric procedures for weight loss. Patients using the endoscopic treatment had complication rates of 1%, compared with 1. Infection is a risk, she says, as are stomach ruptures and bleeding. Patients are advised take it easy for a few days, usually returning to work after that. They are on a liquid diet for 2 weeks, then they eat soft food and gradually introduce a regular diet. Sharaiha says about one of five procedures are reimbursed by insurance. The average cost in the study was $1. About 5. 00 of the endoscopic procedures have been done in the U. S., she estimates. The FDA approved the device used in the treatment in 2. The new procedure won't replace other weight loss approaches but is an option for those who can't have surgery or who would prefer not to, she says. It takes about 4. It's an outpatient procedure. The procedure is done with the understanding that the patient will also exercise regularly and eat a healthy diet. Second Opinions. Ken Fujioka, MD, an endocrinologist and director of the Center for Weight Management, Scripps Clinic, San Diego, agrees the new treatment is not meant to replace other procedures, but will widen choices for obese patients. He called the amount of weight loss it achieved ''exciting'' and said it appears to have lower risk. Cost effectiveness and results both look good, he says. Lindquist and Fujioka say they would like to know whether the new procedure affects hunger- related hormones the way some other procedures do. Gastrectomy, for instance, removes many of the stomach cells that produce the ''hunger hormone. More study is needed, she says. Lindquist consults for Novo Nordisk and Orexigen, which makes the weight loss drug Contrave (naltrexone/bupropion). Sources. Digestive Disease Week presentation, May 6, 2. Chicago. Reem Z. Sharaiha, MD, assistant professor of medicine, Weill Cornell Medicine; attending physician, New York- Presbyterian/Weill Cornell Medical Center, New York. Ken Fujioka, MD, director, Center for Weight Management, Scripps Clinic, Department of Endocrinology, San Diego. Richard Lindquist, MD, obesity medicine specialist, Swedish Medical Center, Seattle; former member, board of directors, Obesity Medicine Association. Clinical Gastroenterology and Hepatology: . All rights reserved.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
August 2017
Categories |